EFMH
KYMR icon

E Fund Management (HK)’s Kymera Therapeutics KYMR Stock Holding History

E Fund Management (HK)’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.7K Buy
233
+60
+35% +$5.16K 0.01% 256
2026
Q1 		$14.4K Buy
+173
New +$13.7K 0.01% 271

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

E Fund Management (HK)'s KYMR Position: Q2 2026 in Review

E Fund Management (HK) increased its Kymera Therapeutics (KYMR) stake by 35% in Q2 2026, buying an estimated $5.16K and bringing the position to 233 shares worth $26.7K. The position accounts for 0.01% of the portfolio, ranked #256.

E Fund Management (HK) first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • E Fund Management (HK) held 233 shares of Kymera Therapeutics worth $26.7K as of Q2 2026.
  • E Fund Management (HK) bought 60 Kymera Therapeutics shares in Q2 2026, an estimated $5.16K.
  • Kymera Therapeutics made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #256 holding.
  • E Fund Management (HK) first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.